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1. Introduction 
Classic infectious causes of immunodeficiency in felines are the immunodeficiency by 
retroviruses, including feline immunodeficiency virus (FIV) and feline leukemia virus 
(FeLV). Immunodeficiency caused by these infectious agents may result from disruption of 
normal host barriers or deregulation of cellular immunity. 
The feline immunodeficiency virus and the feline leukemia virus are detected worldwide 
and are among the most common infectious diseases of domestic cats, others small felids 
and wild cats, and causes immunodeficiency, with increased risk for opportunistic 
infections, neurologic diseases, and tumors. 
Feline immunodeficiency virus and feline leukemia virus are retrovirus, but they differ in 
their potential to cause disease. FIV is classified as a Lentivirus and, FeLV as a 
Gamaretrovirus. The high incidence of FIV and FeLV is associated with density of cat 
population. 
FIV causes immune dysfunctions in cats similar to those observed in people infected with 
human immunodeficiency virus (HIV). Diseases associated with FeLV and FIV may affect 
some organ, and may cause among other disorders, lymphoma, blood dyscrasias, alterations 
in the function of central nervous system, and secondary and opportunistic infections, with 
a significant number of opportunistic pathogens of viral, bacterial, protozoal, and fungal 
origin. Therefore, infected animals may play a role in transmission of various pathogens to 
human beings. 
Risk groups for infection with FIV and FeLV are different: FIV is mainly associated with 
males, free access to streets and bites inflicted during fights for territory, therefore, the risk 
of FIV transmission is low in socially well-adapted cats, while FeLV infection is associated 
with social contacts and thus the FeLV infection is found almost equally between males and 
females, at a rate slightly elevate in male cats. 
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The diagnosis of FIV and FeLV can not be done based solely on clinical signs, but should be 
based on the demonstration of anti-FIV and FeLV antigen in the serum of infected animals. 
FeLV and FIV do not survive for long outside the host and are easily inactivated by 
disinfectants, heating and drying. As prophylaxis against infection of FIV and FeLV is 
recommended castration to reduce aggression and lessen the bite. The rapid and accurate 
diagnosis of any secondary diseases is essential. In shelters, infected cats should be housed 
individually to prevent infection. All animals should be tested before being placed in 
shelters and breeding. Vaccines are available for both viruses; however, identification and 
segregation of infected cats remains the cornerstone for preventing new infections.  
Studies and research about these viruses are continuously necessary to define prophylactic, 
management, and therapeutic measures for stray, feral and owned cats. 
2. Feline immunodeficiency virus  
The first isolation of feline immunodeficiency virus (FIV) has been described by Pedersen, 
1987 in the city of Petaluma, USA. FIV is an important lentivirus that causes immune 
disorders in both domestic and nondomestic cats.  
Like other retroviruses the FIV containing accessory genes in addition to gag, pol and env. 
The FIV gag, pol and env genes encode the capsid protein p24; protease, integrase, and 
reverse transcriptase proteins; the viral glycoprotein (gp120) and the transmembrane protein 
(gp41), respectively. Both gag and pol are relatively conserved between strains (Olmsted et 
al., 1989; Kenyon & Lever, 2011; McDonnel et al., 2012). 
Species-specific strains of FIV circulate in many feline populations. Five genetically distinct 
subtypes or clades of FIV have been described: A, B, C, D and E, with considerable sequence 
diversity in the env gene. Studies have shown that is possible to use the env nucleotide 
sequence and the p17-p24 region of the gag gene for subtypes indentification but, once gag 
gene has a retention rate higher than the env gene, it is considered a good candidate for 
phylogenetic studies (Sodora et al., 1994; Kurosawa et al., 1999; Hosie et al., 2009; Kenyon & 
Lever, 2011). 
2.1. Epidemiology and transmission 
The seroprevalence of FIV is highly variable between geographic locations. Epidemiological 
studies show that FIV transmission is influenced by behavior: cats with free access to the 
streets, sick cats, and males are more susceptible to infection with FIV (Courchamp & 
Pontier, 1994; Sellon and Hatmann, 2006).  
Feline immunodeficiency virus can be transmitted primarily by inoculation of virus present 
in saliva or blood, presumably by bite and fight wounds. Male cats with free access to streets 
are more susceptible to infection because males are territorialist, other ways such as via 
mucosal exposure, blood transfer, during mating, and vertically during prenatal and 
postnatal exposure, can also be responsible for transmission. In natural infections, the 
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efficacy of colostral immunity is not known (Sellon & Hartmann, 2006; Medeiros et al., 
2012). 
2.2. Pathogenesis, immunity and clinical symptoms 
FIV has a tropism for T cells, macrophages, dendritic cells and central nervous system cells. 
The major targets for FIV infection are activated CD4+ T lymphocytes (Fig. 1). These cells 
typically function as T helper cells, which have a central role in immune functions, 
facilitating the development of humoral and cell-mediated immunity (Fig. 1) (Sellon and 
Hartmann, 2006; Hosie et al., 2009; Simões et al., 2012) . FIV does not use CD4 as a primary 
binding receptor, its gp120 glycoprotein binds to the CD134 (OX40) a member of the tumor 
necrosis factor receptor (TNFR)/nerve growth factor receptor family of molecules as the 
binding receptor in conjunction with the chemokine receptor CXCR4 as a cofactor for 
infection (Yuan et al., 2003; de Parseval et al., 2005; Willett et al., 2006b; Elder et al., 2010). 
The CD134 co-stimulatory pathway has been shown to be critical for T, B and antigen-
presenting cell (APC) cell activation. Studies have shown that antigen stimulation of 
infected B-cells is increased compared with non-infected cells. FIV-infection in cats also 
results in a sustained polyclonal activation of B-cells with the production of antibodies to a 
variety of non-viral antigens (Yuan et al., 2003; Willett et al., 2006b). 
 
Figure 1. Diagram illustrating the stages of the pathogenesis of FIV. Modified from Sellon and 
Hartmann, 2006. 
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As for HIV, it has been classified some stages for FIV infection (Table 1 and Fig. 2 and 3): 
clinical symptoms during initial stages (acute phase) of infection include fever, leucopenia, 
gingivitis, lethargy, signs of enteritis, stomatitis, dermatitis, conjunctivitis, respiratory tract 
disease, neutropenia, and generalized lymphadenopathy (Sellon e Hartmann, 2006; Gunn-
Moore & Reed, 2011; Hartmann, 1998; Hartamann, 2011; O’Brien et al., 2012). The 
progression of disease occurs in a manner similar to the HIV-1 infection in humans. In the 
first few days after infection, FIV replicates in dendritic cells, macrophages and CD4+ T 
lymphocytes, within 2 weeks appears in the plasma. FIV-specific CD8+ cytotoxic T cells are 
detected in the blood within one week of infection. The duration of the following 
asymptomatic phase varies but usually lasts many years, viral replication is controlled by 
the immune response, but there is a progressive decline in CD4+ T lymphocyte numbers, 
resulting in a decreased CD4+/CD8+ T lymphocyte ratio (Fig. 1) (Hartmann, 1998; Sellon e 
Hartmann, 2006; Gunn-Moore & Reed, 2011; Hartamann, 2011). The most infected cats 
exhibit an increase in CD8+ T cells along with a strong humoral antibody response which 
allows them to control this initial phase of the infection (Elder et al., 2010). After 2-4 weeks 
after infection, antibodies are detectable in plasma for FIV. Antibodies recognizing env 
related proteins appear earlier than those against the gag protein p24. Factors that influence 
the length of the asymptomatic stage include the pathogenicity of the infecting strain (also 
depending on the FIV subtype), exposure to secondary pathogens, and the age of the cat at 
the time of infection. In the last, symptomatic stage (FAIDS phase) of infection, clinical signs 
are a reflection of opportunistic infections, skin infections such as demodicosis and 
pediculosis, neoplasia such as B cell lymphosarcoma and squamous cell carcinoma, 
myelosuppression, and neurologic disease, similar to those observed in people infected with 
human immunodeficiency virus (HIV) (Hartmann, 1998; Sellon e Hartmann, 2006; Elder et 
al., 2010; Gunn-Moore & Reed, 2011; Hartamann, 2011; Korman et al., 2012; Sobrinho et al., 
2012). The chronic gingivostomatitis is the most common clinical sign in infected cats and 
significantly degrade the quality of life of animals  
 
Phases Clinical sings Duration 
Acute 
Unspecific signs 
Neutropenia, Fever, lethargy, peripheral, 
lymphadenopathy, weight loss 
Weeks-months 
Asymptomatic No clinical signs, but there is a progressive 
decline in CD4+ T lymphocyte numbers 
Years 
Unspecific clinical 
signs 
Apathy, weight loss, lymphadenopathy, fever, 
anorexia, depression, chronic gingivostomatitis 
(difficulty eating), chronic rhinitis, lymph 
adenopathy, immune-mediated glomerulo 
nephritis, leucopenia, bahvioral abnormalities 
Several 
months 
FAIDS Above symptoms more opportunistic infections, 
clinical symptoms of immunodeficiency, 
neoplasia, neurological abnormalities and 
seizures. 
Several 
months 
 
 
Table 1. Stages of clinical sings of FIV infection. 
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Figure 2. FIV infected cats.  (Courtesy Bruno Teixeira, Universidade São Paulo, USP). 
 
Figure 3. Stomatitis and gingivitis. (Courtesy Bruno Teixeira, Universidade São Paulo, USP). 
Pathologic abnormalities described in FIV positive cats with alterations in the morphology 
of lymph node: hyperplastic during acute phase, follicular involution in the terminal phase 
of infection; thymus: cortical involution, atrophy, lymphoid follicular hyperplasia and 
germinal center formation; intestinal tract: villous blunting, pyogranulomatous colitis, 
lymphoplasmacytic stomatitis; liver: periportal hepatitis; bone marrow: dysplastic changes, 
granulocytic hyperplasia and the formation of marrow lymphoid aggregates; kidney: 
tubulointerstitial infiltrates, glomerulosclerosis; central nervous system: Perivascular 
cuffing, gliosis, myelitis, loss and reorganization of neurons, axonal sprouting, vacuolar 
myelinopathy; lung: interstitial pneumonitis, alveolitis; skeletal muscle: lymphocytic 
myositis, myofiber necrosis, perivascular cuffing; reproductive failure occurs in FIV infected 
cats (Sellon e Hartmann, 2006; Gunn-Moore & Reed, 2011; Hartmann, 2011). 
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2.3. Diagnosis and management of FIV-infected cats 
The methods used currently for detection of FIV infection in domestic cats include virus 
isolation, immunological tests for detection of specific antibodies and molecular tests for 
detection of viral genomic sequences, associated with the clinical diagnosis. Virus isolation 
is a reliable diagnostic method but is laborious and not used routinely.  
The preferred initial tests are ELISA or immunochromatographic test, which detect 
antibodies recognizing viral structural proteins (such as the capsid protein p24 and a gp41 
peptide) and offer the advantage of speed and convenience. However, when the results are 
inconclusive by these tests a more specific test should be used, such as the Western blot 
(Hosie et al., 2009). The PCR can have doubtful results due to the great genetic variability of 
FIV, use of specific primers only for one subtype, low viral load during a long period of 
infection, and inadequate preparation of PCR components. The specificity and sensitivity of 
PCR may vary from 40-100% according to the methodology and standardization of the 
laboratory (House & Jarret, 1990; Hartmann et al., 2007; Hosie et al., 2009). There is also a 
technique of lymphocytes, for the visualization of CD4+/CD8+, however, due to the 
complexity of these tests are not used routinely. 
The cats positive for FIV should not be euthanized based only on a positive test result for 
FIV. These animals have a long life as large as that of uninfected cats, however, should be 
subject to regular veterinary (at least every 6 months) queries including monitoring 
biochemistry, hematological, and weight routine, however, the euthanasia should be 
considered when the clinical problems relate to an advanced stage of FIV infection leading 
the animal to a poor living conditions. 
However, it is important to isolate the animal infected with FIV from others non-infected, 
and maintain a good state of health of the animal infected, because other conditions can lead 
to the progression of immune deficiency. Positive cats should be neutered to reduce 
aggressive and laughter of contamination during fighting and copulation. 
Vaccination is a controversial subject. Vaccines with inactivated viruses are available in the 
U.S.A, Australia, New Zealandand and Japan. These vaccines induce a rapid humoral 
response with antibodies indistinguishable from natural infection. However, there are 
several studies aimed at differential tests to indentify natural FIV infected animals from 
those vaccinated ones.  
Early diagnosis is very important because it will enable early treatment of disease. There are 
treatments with corticosteroids and other immunosuppressive drugs in animals with 
chronic stomatitis, however, they cause many side effects. The Filgastrim (granulocyte 
colony-stimulation factor), a recombinant human cytokine (rHuG-CSF), has been used in 
cats with profound neutropenia, to increase the neutrophil count, however, can also increase 
the viral load. The recombinant human erythropoietin is also used successfully in cats with 
non-regenerative anemia, administration elevates blood cells, without increasing the viral 
load. Treatment with insulin-like growth factor-1 recombinant human induces thymic 
growth and stimulates T cell function, resulting in a significant increase in thymus size and 
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thymic cortical regeneration, replenishing the peripheral T cell pool in experimentally FIV-
infected cats (Hosie et al., 2009; Mohammadi & Bienzle, 2012). 
Most of the antiviral drug for FIV is licensed for the treatment of HIV infections in humans, 
with AZT (3’-azido-2’,3’-dideoxythymidine), however, many human antiviral, are 
ineffective or toxic to cats. AZT (3’-azido-2’,3’-dideoxythymidine) is a nucleoside analogue 
(thymidine derivative) that blocks the retroviral reverse transcriptase and inhibits the 
replication of FIV in vivo and in vitro. As with HIV, FIV resistance may arise after 6 months 
of treatment (Hosie et al., 2009; Doménech et al., 2011; Mohammadi & Bienzle, 2012). 
Some studies have shown promising results with the use of recombinant interferon for the 
treatment of FIV, increasing the survival of infected animals. Immunomodulators and 
interferon inducers are most utilized in infected animals, but there are controversies 
regarding the use, for nonspecific stimulation of the immune system, can also assist in an 
increase in viral load. 
3. Human immunodeficiency virus type 1 (HIV-1) x Feline 
immunodeficiency virus (FIV) 
Like the HIV, FIV belongs to the genus Lentivirus of the Retroviridae family. Since the 
discovery of human immunodeficiency virus type 1 (HIV-1) in 1982 there is an urgent need 
for animal models to study the pathogenesis of HIV-1 infection and possibilities for 
interventional strategies (Elder et al., 2008). FIV was descript in 1987, and since then, FIV has 
been proposed as a model for HIV studies, because, among non-primate vertebrates, FIV 
infection in the cat may be the closest model of HIV infection and acquired 
immunodeficiency syndrome (AIDS). 
FIV is phylogenetically (though not antigenically) related to HIV-1. FIV and HIV share 
many features in their genomes in comprising three major open reading frames (ORF), gag, 
pol and env, especially in the pol gene and FIV also has a very similar life cycle to that of 
HIV (Table 2) (Savarino et al., 2007; Elder et al., 2008; Elder et al., 2010).  
 
 FIV HIV 
Viral genes encoded
Gag,Pol,Env,LTRs Yes Yes 
Vif Yes Yes 
Ver Yes Yes 
Tat No Yes 
Vpr No Yes 
Vpu No Yes 
OrfA Yes No 
DU Yes No 
Nef No Yes 
Table 2. Comparative viral genes encoded. Modified from Elder et al., 2010. 
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The similarities and discrepancies in the physiopathology of feline and human viruses in 
their respective natural hosts presents striking analogies, and several intriguing differences 
(Tables 3 and 4). FIV and HIV share a common pattern on clinical signs, having initially a 
nonspecific acute phase, followed by an asymptomatic phase and a phase in which the 
immune system is compromised and the animal is subjected to secondary infections (Sellon 
e Hartmann, 2006; Gunn-Moore & Reed, 2011; Hartmann, 1998; Hartamann, 2011; Magden 
et al., 2011; O’Brien et al., 2012). 
The dynamics of infection by FIV and HIV in their natural hosts are very similar, like HIV, 
FIV can be transmitted via mucosal exposure, blood transfer, and vertically via prenatal and 
postnatal routes, but FIV is principally transmitted through biting, while natural 
transmission of HIV occurs mainly via mucosal routes. 
The development of disease and clinical signs are also similar in human and cat (Fig. 1 and 
Table 3), both virus preferentially infects CD4 + T cells, while the cell surface receptors CD4 
and CD134 are used for HIV and FIV, respectively, differ: the SU glycoprotein of FIV 
initially binds to CD134, triggering the conformational changes in SU that allow subsequent 
interaction between SU and the receptor CXCR4 (Grant et al., 2009). While some viruses 
arising in the later stages of HIV infections are able to use CXCR4, most natural isolates of 
HIV use a different chemokine receptor, CCR5. Nevertheless, since CCR5 and CD134 in 
humans and cats, respectively, are predominantly expressed on CD4+ T cells (Table 4) 
(Willet et al., 2006a; Grant et al., 2009; Elder et al., 2010). 
 
 FIV HIV 
Oral lesions Yes Yes 
Lymphadenopathy Yes Yes 
Neutropenia Yes Yes 
CD4 T cell depletion Yes Yes 
Hypergammaglobulinemia Yes Yes 
Wasting, diahrrea Yes Yes 
Secondary infections Yes Yes 
CNS lesions Yes Yes 
Neoplasia Yes Yes 
Table 3. Comparative disease symptoms. Modified from Elder et al., 2010. 
Host immune response against FIV in domestic cats is very similar to those induced in HIV-
infected patients. Both viruses cause dysfunction of the CD4+ lymphocyte early in infection, 
although FIV also infects the CD8+ subset, B lymphocytes and macrophages and ultimately 
cause immune system collapse. Epitopes recognized by humoral and cytotoxic cellular 
immune responses have been described in both Env and Gag genes. Some studies suggest 
that progression to AIDS may be associated with a TH2-type response, while resistance may 
be higher in individuals with a strong THI-type response. 
The evaluation of vaccine strategies in animal models is essential to instruct development of 
a vaccine against HIV. Currently, there are studies using transgenic cats expressing HIV 
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proteins, serving as valuable models to study the pathophysiology of HIV.A vaccine against 
FIV, whose development has been the object of considerable international research effort, 
has intrinsic value as well as the potential to provide a powerful proof of concept in 
vaccination against human AIDS (Klonjkowski  et al., 2009). 
 
 FIV HIV 
Transmission   
Blood contact Yes Yes 
Mucosal contact Yes Yes 
Vertically via prenatal Yes Yes 
Postnatal routes Yes Yes 
Target cell   
CD4+ T cell Yes Yes 
Macrophage Yes Yes 
Dentritic cell Yes Yes 
Subset B cells Yes ? 
Microglia Yes Yes 
Receptors utilized   
CD4 No Yes 
CD134 Yes No 
CXCR4 Yes Yes 
CCR5 No Yes 
Table 4. Comparative properties of FIV and HIV. Modified from Elder et al., 2010. 
4. Feline leukemia virus 
Feline leukemia virus has been reported mainly in domestic cats and, was first described in 
1964 by William Jarret and co-workers. It is considered more pathogenic than FIV and FeLV 
infection has higher impact on mortality, because causes more severe immunosuppression 
than that caused by FIV infection (Hartmann, 2006; Lutz et al., 2009).  
The FeLV genome contains envelope (env), polymerase (pol) e group specific antigen (gag) 
genes that encode for the surface (SU) protein glycoprotein gp70 and the transmembrane 
(TM) protein p15E; reverse transcriptase, protease and integrase; internal virion proteins, 
including p15c, p12, p27 and p10; respectively. The p27, which is used for clinical detection 
of FeLV and gp70 defines the virus subgroup (Hartmann, 2006; Lutz et al., 2009). 
Although it has not been described serotypes for FeLV virus isolates have variants or 
subgroups (FeLV-A, FeLV-B, FeLV-C and FeLV-T). These subgroups are distinguished by 
the nucleotide sequence of the env gene and, antigenically they are closely related. 
Variations in protein SU sequences would be responsible for use by the virus of different cell 
receptors, resulting in differences in tropism including bone marrow, salivary glands and 
respiratory epithelium, and pathogenicity of field isolates (Neil et al., 1991; Roy-Burman et 
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al., 1995). Subtype A is more disseminated, it is involved in all clinical infections and is 
related to immunodeficiency. Only FeLV A is contagious and passed horizontally from cat 
to cat in nature. The host cell receptor used by FeLV is Feline highaffinity thiamine transporter 
1 (feTHTR1), found in absorption tissues and small intestine besides liver and kidneys, and 
also in cells of the lymphoid system. This wide distribution is consistent with the fact that 
the FeLV-A is found in a variety of tissues and cells and this subgroup can cause 
lymphomas, but usually causes injury moderate in the absence of other subgroups. Subtype 
B originates from recombination of FeLV-A is primarily associated with tumors. Subtype C 
considered the most pathogenic subgroup, emerges from mutations in the env gene of 
subtype A and is mainly associated with non-regenerative anemia. Subtype T was originally 
isolated from a cat with FeLV induced immunodeficiency (FAIDS). This subgroup arises 
from mutations in the SU gene sequence of the FeLV-A with approximately 96% similarity. 
It is defined by its T lymphotropism. This subgroup requires a membrane-spanning receptor 
molecule (PIT1) and a co-receptor protein (FeLIX) to infect T lymphocytes and causes 
usually severe immunosuppression. In fact, all naturally infected cats carry FeLV A either 
alone or in combination with FeLV B, FeLV C, or both (Neil et al., 1991; Roy-Burman et al., 
1995; Hartamann, 2006; Lutz et al., 2009). 
4.1. Epidemiology and transmission 
The feline leukemia virus has a worldwide distribution. FeLV is contagious and spreads 
through close contact between viral shedding, but the prevalence of infection varies greatly 
depending on their age, health, environment, density of animals and lifestyle (Hard et al., 
1976; Grant et al., 1980). The kittens are more susceptible, since the resistance develops with 
age. Because of advances in the diagnosis of disease and vaccination the prevalence of FeLV 
has dropped substantially in the last two decades. In Shelters and places where there is a 
high density of animals, it is advisable to proceed diagnosis of all animals. Infected animals 
should be euthanized or isolated from not infected animals. 
FeLV is transmitted mainly by oronasal contact, through saliva, urine, feces, ingestion of 
contaminated food and water and also through bites. Transmission can also take place from 
an infected mother cat to her kittens, either before they are born or while they are nursing. 
Older cats are more resistant to FeLV infection, but can be infected by high viral doses (Lutz 
et al., 2009). 
4.2. Pathogenesis, immunity and clinical symptoms 
FeLV is present in the blood during two different stages of infection: primary viremia, an 
early stage of virus infection. During early stage some cats are able to mount an effective 
immune response, eliminate the virus from the bloodstream. The second stage is 
characterized by persistent infection of the bone marrow and other tissues (Table 5) (Hard et 
al., 1976; Hartmann, 2006; Fugino et al., 2008). If FeLV infection progresses to this stage it 
has passed a point of no return: the overwhelming majority of cats with secondary viremia 
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will be infected for the remainder of their lives. The pathogenesis of FeLV is different in each 
cat and depends on immune status and age, but can be classified into six stages (Table 6) 
(Hard et al., 1976; Charreyre & Pedersen, 1991; Hartmann, 2006; Fugino et al., 2008; Lutz, 
2009).  
 
Classification of 
evolution of the 
disease 
Classification 
of infected 
animals 
Response immune Days after 
infection 
Healthy cat 
Regressive infection 
extinct 
Transient 
viremia 
 
Efficient - virus 
neutralization 
 
Days FeLV negative - 
Animal resistant 
future infections for 
a period of time 
Progressive Persistent 
viremia 
Failure to develop 
an immune 
response effective 
3 weeks FeLV positive 
Regressive Latent 
infection 
Body inactive the 
virus, but not 
neutralizes 
3-13 weeks FeLV negative 
(complete elimation) 
FeLV positive 
(continued viremia) 
Atypical  Complete virus is 
sequestered in the 
epithelial tissue, 
replicates itself, but 
leaves the cells 
3-13 weeks FeLV positve 
Table 5. Immune responses following infection. Modified from Hartmann, 2006. 
Clinical signs associated with FeLV infection are variable (Fig. 4). It has seen tumors in 
infected cats once FeLV is a major oncogene that causes different kind of tumors, most 
commonly malignant lymphoma and leukemia and other hematopoietic tumors. It also 
induces thymic atrophy and depletion of lymph node paracortical zones following infection 
Besides that it has been found immunosuppression with poor response to T-cell mitogens, 
reduced immunoglobulin production; hematologic disorders like lymphopenia and 
neutropenia; immune-mediated diseases; neuropathy; reproductive disorders; fading kitten 
syndrome and opportunistic infections. The lymphopenia may be characterized by 
preferential loss of CD4+/CD8+ ratio and losses of helper cells and cytotoxic supressor cells 
and primary and secondary humoral antibody responses are delayed and decreased 
(Hartmann, 2006; Lutz et al., 2009; Hartmann, 2011). 
FeLV infected cats having concurrent protozoal, bacterial, viral, and fungal infections, most 
commonly bartonellosis, respiratory infections and coccidiosis (Wolf-Jäckel et al., 2012; 
Sobrinho et al., 2012). Diseases such as hemolytic anemia, glomerulonephritis, chronic 
enteritis with intestinal epithelial cell degeneration and necrosis of the crypts, liver disease, 
reabsorption fetal, abortion, stillbirth, lymphadenopathy, polyarthritis and neurological 
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diseases such as peripheral neuropathies, may be related to FeLV infection (Hartmann, 2006; 
Lutz et al., 2009; Hartmann, 2011). 
 
Stages Replication region Pathogenesis Days post 
infection 
I Oropharynx and 
lymph nodes 
Infects lymphocytes, which 
travel to the bone marrow 
2- 12 days 
II Lymphocytes and 
monocytes 
Immune suppression, thymic 
atrophy, lymphopenia, 
neutropenia, neutrophil 
function abnormalities, loss of 
CD4+ cells and CD8+ 
lymphocytes 
2- 12 days 
III Systemic lymphoid 
centers 
Immune suppression 2- 12 days 
IV Bone marrow cells 
and epithelial cell 
Anaemia and lymphoma 2- 6 weeks 
V Bone marrow stem 
cells 
Myelossuppression and 
leukemia 
4- 6 weeks 
VI Viremia medullary 
epithelial and 
lymphoid 
Thrombocytopenia and 
neutropenia 
4- 6 weeks 
Table 6. Stages of replication of the virus of feline leukemia (FeLV). 
 
Figure 4. Gingivitis. (Courtesy Marcia Moller Nogueira). 
The feline oncovirus associated-membrane antigens (FOCMA) may be associated with 
immunodeficiency that occurs because of depletion of lymphoid cells infected, probably due 
to antibody-mediated cytotoxic. Leukemia and anemia are induced by the transformation of 
stem cells, myeloid and lymphoid lineages, induced by infection with FeLV (Hard et al., 
1976; Lutz et al., 2009; Hartmann, 2011). 
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4.3. Diagnosis and management of FeLV-infected cats 
The correct and early diagnosis is important for prevention and control of FeLV infection 
Diagnostic tests detect antigens and, cats of any age should be tested. For the diagnosis of 
FeLV, virus isolation is not widely used, because it is difficult, time consuming to perform 
and requires special facilities, though viral antigens could be detected in peripheral blood 
cells, this method has been considered as the ultimate diagnostic criterion. Most often, the 
diagnosis of infection is done based on clinical history and detection of antigens, the FeLV 
core protein (p27), in leukocytes, plasma, serum or saliva of suspected animals (Barr, 1998; 
Hartmann, 2006). The direct immunofluorescence assay in blood smears, is the most 
commonly used diagnostic methods for detection of the virus, targeting mainly proteins p27 
and p55 that are present in infected leukocytes (Hard, 1991). Tests such as ELISA and 
immunochromatography for the p27 protein have high sensitivity and specificity and are 
preferred used because they are less laborious, however, when doubtful results occurs it 
should be confirmed by direct immunofluorescence (Table 7) (Hard, 1991, Hartmann et al., 
2007; Lutz et al., 2009). PCR is being used currently for detection of viral nucleic acid (RNA 
or proviral DNA) and is highly strain specific. PCR positive for FeLV proviral DNA 
indicates the presence of exogenous but not necessarily can be used as a diagnosis for 
viremia (Gomes-Keller et al., 2006). In these cases the RT-PCR detects the presence of viral 
RNA and informs the development of viremia in infected animals, but current reagents and 
testing protocols should be well standardized. As a retrovirus, mutations in FeLV occur 
naturally and may react negatively with a specific PCR. 
It is necessary a good classification of the stage (Table 6) of the disease to obtain an accurate 
diagnosis. In phases I-III only ELISA can detect viral antigens for FeLV, and in the stages IV-
VI can be detected by ELISA, immunofluorescence and PCR. The combination of testing 
determines the FeLV infection status of most cats. Recommend annual retesting after any 
discordant test result until agreement. A positive test doubtful a healthy animal, it should be 
done further confirmatory tests such as direct immunofluorescence and PCR for provirus 
(Gomes-Keller et al., 2006; Hartmann, 2006; Lutz et al., 2009). 
For an accurate diagnosis, it is also necessary to evaluate the age and lifestyle of the animal 
(Table 7): Negative animals under 12 weeks who had contact with sick birds or other 
animals should be retested within 4-6 weeks; positive results indicate that at this age the 
animals are infected. Negative animals with more than 12 weeks who had contact with sick 
birds or other animals should be retested within 6-8 weeks; positive results at this age 
should be classified as follows: sick animals (positive), healthy animals, retesting within 6-8 
weeks.  
The early and precise diagnosis is needed to enable rapid intervention. FeLV-infected cats 
should be isolated from uninfected ones. It is also recemmented that they could be examined 
by the vet regularly (every 6 months), doing biochemical tests, complete blood count and 
urinalysis. Infected animals should be sterilized to minimize the transmission. The living 
environment should be cleaned periodically, because FeLV is sensitive to any type of 
disinfectant. 
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Age Result of the 
diagnosis
Lifestyle of the 
animal 
Interpretation Measure 
Less than 12 
weeks 
Negative 
Kept contact 
with other 
animals and /or 
sick animals
Re-test after 4-6 
weeks 
The result of 
the last test 
will be 
conclusive 
Not kept contact 
with other 
animals and / or 
sick animals
Uninfected  
Positive 
Even that has 
ingested 
colostrum 
positive for 
FeLV
Infected Isolation of 
animal and 
clinical control 
every six 
months. 
More than 12 
weeks 
Negative 
Animal exposed 
to sick or 
diseased 
animals
Re-test after 6-8 
weeks 
The result of 
the last test 
will be 
conclusive 
Animal no 
manifestations
Uninfected  
Positive 
Sick animal
 
Infected  
Animal health Re-test after 6-8 
weeks 
The result of 
the last test 
will be 
conclusive 
Table 7. Interpretation of results obtained by ELISA and direct immunofluorescence. Modified from 
Hartmann, 2006. 
As immunomodulatory therapy are used to good clinical improvement, but are still under 
study. Antivirals such as AZT that acts effectively against FeLV replication in vitro and in 
vivo reducing the viral load, improving the immune response and clinical condition of the 
animal (Cotter, 1991; Hartmann, 2006; Lutz et al., 2009). Infected animals should be treated 
for other infections promptly to prevent an impaired immune system and should be 
vaccinated regularly against other pathogens like rabies virus, feline panleukopenia, 
rhinotracheitis, calicevirose, chlamydiosis and other (Cotter, 1991; McCaw, 1995, Lutz et al., 
2009). Corticosteroids should be avoided, but if stomatitis or gingivitis occurs they can be 
used to facilitate the intake of food. In cats with anemia, blood transfusions may be useful 
and leukopenia can be treated with colony-stimulating factors (Cotter, 1991; McCaw, 1995, 
Lutz et al., 2009). 
All animals should be tested for FeLV and thereafter be vaccinated at the age of 8-9 weeks 
and again at 12 weeks with annual boosters. Older animals are less susceptible to infection 
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and can be vaccinated at intervals of 2-3 years. Vaccines prepared with inactivated whole 
virus obtained from cell cultures are available commercially, as well as vaccines containing 
recombinant viral proteins expressed in heterologous systems. No FeLV vaccine provides 
100% efficacy of protection for FeLV and none prevents infection, but vaccination offers 
good prevention of fatal cases. The immunization of animals with inactivated vaccines may 
result in a reduction of 70% incidence of the disease. FeLV immunization should be part of 
the routine vaccination programmed for pet cats. However, the most effective way to 
prevent the spread of infection is testing for FeLV and preventing exposure of healthy cats 
to FeLV infected cats (Cotter, 1991; McCaw, 1995, Hartmann, 2006; Lutz et al., 2009). 
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